(PRGO) Perrigo - Ratings and Ratios

Perrigo Company PLC (NYSE: PRGO) stands as a prominent figure in the self-care consumer products sector, offering an expansive array of over-the-counter health solutions designed to enhance personal well-being. With operations spanning the Americas and international markets, Perrigo has established a robust presence, catering to diverse consumer needs across the globe.

The companys product portfolio is both broad and deep, encompassing upper respiratory products, nutrition items, digestive health solutions, pain and sleep aids, and oral care products. This extensive range ensures that Perrigo addresses a multitude of health concerns, from cough suppressants and infant formulas to antacids and toothbrushes. Their commitment to health extends further with lifestyle products such as smoking cessation aids and womens health offerings, including contraceptives and feminine hygiene products.

Perrigos brand arsenal is equally impressive, featuring well-known names like Compeed, Dr. Fresh, and Nasonex, each contributing to the companys market presence. These brands not only reflect a dedication to quality but also resonate with consumers seeking reliable health solutions. Beyond their own products, Perrigo offers contract manufacturing services, leveraging their expertise to support other entities in the industry.

In terms of distribution, Perrigos strategy is multifaceted, ensuring products reach consumers through various channels. From retail pharmacies and supermarkets to e-commerce platforms and wholesalers, the companys wide distribution network maximizes accessibility. This strategic approach ensures that Perrigos products are within easy reach for consumers across different regions and demographics.

Financially, Perrigo presents an intriguing profile for investors. With a market capitalization of approximately $3.4 billion, the company offers a substantial market presence. The forward P/E ratio of 8.17 suggests potential for future growth, while the price-to-book ratio of 0.74 indicates undervaluation relative to its assets. The price-to-sales ratio of 0.77 further underscores the companys attractive valuation metrics, making it a compelling consideration for value-driven investors.